Review of hepatitis B therapeutics

Debika Bhattacharya, Chloe L. Thio

Research output: Contribution to journalReview articlepeer-review

Abstract

Currently, there are 7 approved therapies for chronic hepatitis B virus (HBV) infection, an increase from just 3 agents 5 years ago. This review will focus on the pharmacology, potency, and adverse events associated with immunomodulatory agents and nucleos(t)ide analogues, with an emphasis on targets of therapy within the HBV life cycle. We will also offer guidelines for the use of available anti-HBV agents and review the emerging challenges in hepatitis B management, including HBV drug resistance, its management, and the potential role of combination therapy.

Original languageEnglish (US)
Pages (from-to)1201-1208
Number of pages8
JournalClinical Infectious Diseases
Volume51
Issue number10
DOIs
StatePublished - Nov 15 2010

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Review of hepatitis B therapeutics'. Together they form a unique fingerprint.

Cite this